Abstract:Background and PurposePelitinib is a potent irreversible EGFR TK inhibitor currently in clinical trials for the treatment of lung cancer. Hyperthermia has been applied concomitantly with chemotherapy and radiotherapy to enhance treatment outcome. In this study, we investigated the ability of the combination of pelitinib with other conventional anticancer drugs to specifically target cancer cells with up-regulated efflux transporters ABCB1/ABCG2 after hyperthermia as a novel way to eradicate the cancer stem-like cells responsible for cancer recurrence. Experimental ApproachAlterations in intracellular topotecan accumulation, the efflux of fluorescent probe substrates, expression and ATPase activity of ABCB1/ABCG2 and tumoursphere formation capacity of side population (SP) cells sorted after hyperthermia were examined to elucidate the mechanism of pelitinib-induced chemosensitization. Key ResultsWhile pelitinib did not modulate ABCB1/ABCG2 expressions, the combination of pelitinib with transporter substrate anticancer drugs induced more marked apoptosis, specifically in cells exposed to hyperthermia. The flow cytometric assay showed that both ABCB1- and ABCG2-mediated drug effluxes were significantly inhibited by pelitinib in a concentration-dependent manner. The inhibition kinetics suggested that pelitinib is a competitive inhibitor of ABCB1/ABCG2, which is consistent with its ability to stimulate their ATPase activity. SP cells sorted after hyperthermia were found to be more resistant to anticancer drugs, presumably due to the up-regulation of ABCB1 and ABCG2. Importantly, pelitinib specifically enhanced the chemosensitivity but reduced the tumoursphere formation capacity of these SP cells. Conclusions and ImplicationsThis study demonstrated a novel approach, exploiting drug resistance, to selectively kill cancer stem-like cells after hyperthermia.

EGFR Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment.

Correction: EGFR Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment.

Enhancing Intrapleural Hyperthermic Chemotherapy for Lung Cancer: Insights from 3D and PDX Models

Tyrosine Kinase Inhibitors Interstitial Pneumonitis: Diagnosis and Management.

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Intrapleural perfusion hyperthermia improves the efficiency of anti‐PD1 antibody‐based therapy for lung adenocarcinoma: A case report

Progress on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for Treatment of Advanced Non-Small Cell Lung Cancer

Therapeutical Effect of Intrapleural Perfusion with Hyperthermic Chemotherapy on Malignant Pleural Effusion under Video-Assisted Thoracoscopic Surgery

Clinical Efficacy Of Egfr-Tkis In Combination With Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer Harboring Egfr Mutations

Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy

Sensitization of Epidermal Growth Factor Receptor (EGFR) Inhibitors Induced by Radiotherapy Combined with Programmed Death Ligand-1 (PD-L1) Inhibitors

Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR -mutated lung cancer patients.

First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence.

Role of Allogeneic Natural Killer T Cells in the Treatment of a Patient with Gefitinib-Sensitive Lung Adenocarcinoma.

Pemetrexed-carboplatin with Intercalated Icotinib in the Treatment of Patient with Advanced EGFR Wild-Type Lung Adenocarcinoma

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment

Thermal cycling hyperthermia sensitizes non-small cell lung cancer A549 cells to EGFR-tyrosine kinase inhibitor Erlotinib

Efficacy of Epidermal Growth Factor Receptor (Egfr)-Tyrosine Kinase Inhibitors (tkis) in Targeted Therapy of Lung Squamous Cell Carcinoma Patients with EGFR Mutation: a Pooled Analysis.

How Sensitive Are Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation? A Bicenter Research and Pooled Analysis of Published Reports.

Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.